T 1462/22 (Antibody screening method/CHUGAI) of 13.03.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T146222.20250313
- Date of decision
- 13 March 2025
- Case number
- T 1462/22
- Online on
- 1 July 2025
- Petition for review of
- -
- Application number
- 13195718.5
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
- Applicant name
- Chugai Seiyaku Kabushiki Kaisha
- Opponent name
- Glaxo Group Limited
Novo Nordisk A/S
James Poole Limited
Shire Human Genetic Therapies, Inc.
Ablynx N.V.
Alexion Pharmaceuticals, Inc. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 123(2)European Patent Convention Art 76(1)European Patent Convention Art 83European Patent Convention Art 84Rules of procedure of the Boards of Appeal Art 11Rules of procedure of the Boards of Appeal Art 13(2)
- Keywords
- Amendments - added subject-matter (no)
Sufficiency of disclosure - (yes)
Claims - clarity (yes)
Remittal - special reasons for remittal (yes) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution on the basis of claim 1 of the main request submitted with letter of 12 February 2025.